[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

May 2016 | 462 pages | ID: C136B6BCC8EEN
La Merie Publishing

US$ 1,393.00

Online Subscription

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This Competitive Intelligence report about Biosimilar & Biosuperior Therapeutic Antibodies updates the competitive landscape of biosimilar therapeutic antibodies as of May 2016. The report evaluates the the first wave of biosimilar recombinant monoclonal antibodies in comparison with the corresponding originator antibodies and biosuperior antibodies against the same target. The report also describes the next wave of potential biosimilar versions of therapeutic antibodies loosing patent protection in the time frame of 2019 – 2023. The report specifically lists for each target the branded products with their 2015 sales and up-side indications in development, as well as biosuperior and biosimilar antibody drug candidates in development.

The report includes a compilation of marketed, approved and currently active projects in research and development of biosimilar and biosuperior therapeutic antibodies against commercially and clinically validated targets relevant for the first wave of biosimilar antibodies (VEGF, TNF, Her2, CD20, EGF-R). Relevant first wave originator therapeutic antibodies are Humira, Enbrel, Remicade, Avastin, Lucentis, Eylea, Herceptin, Rituxan / MabThera and Erbitux. Second generation therapeutic antibodies against these targets such as Symponi, Cimzia, Cyramza, Perjeta, Arrzera are also subject of biosimilar activities.

The report also addresses the slowly emerging second wave of biosimilar antibody activities against originator therapeutic antibodies such as abatacept, alemtuzumab, denosumab, eculizumab, omalizumab, pavilizumab, tocilizumab, and ustekinumab.

Download sample pages of Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies – 2016 Update

Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
A) 2015 Sales of Therapeutic Antibodies
  Overview: 2015 Biologics Sales per Class of Products
  Overview: 2015 Therapeutic Antibody Sales per Class of Products
  Blockbuster Therapeutic Antibodies in 2015
  Anti-TNF Antibody Sales in 2015
  Cancer Antibody Sales in 2015
  Other Anti-Inflammatory Antibody Sales in 2015
  Ophthalmic Antibody Sales in 2015
  Cardiometabolic & Anti-Infective Antibody Sales in 2015
B) Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update
  1. Originator Anti-TNF Antibodies
    Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
    2015 Sales of Anti-TNF Antibodies
    Sales of Anti-TNF Antibodies in Q1/2016
    Humira Pipeline of Recently Approved Indications & Upside Developments
    Remicade Pipeline of Recent Approvals & Upside Indications
    Enbrel Pipeline of Upside Indications
    Simponi Pipeline of Recent Approvals & Upside Indications
    Cimzia Pipeline of Recent Approvals & Upside Indications
    Defense Strategies against Biosimilar Anti-TNF Antibodies
  2. Biosuperior Anti-TNF Antibodies
    Non-Antibody Anti-TNF Biosuperiors
  Anti-TNF Biosuperior Antibodies
  3. Biosimimilar Anti-TNF Antibodies
    Humira Biosimilar Antibodies:
      Developments in Regulated Markets
      Developments in Less Regulated Markets
    Enbrel Biosimilar Antibodies:
      Developments in Regulated Markets
      Developments in Less Regulated Markets
    Remicade Biosimilar Antibodies:
      Developments in Regulated Markets
      Developments in Less Regulated Market
    Simponi & Cimzia Biosimilar Antibodies
C) Biosimilar and Biosuperior Anti-VEGF/-R Antibodies – 2016 Update
  1) Marketed Anti-VEGF/R Products in Oncology
    Avastin, Zaltrap & Cyramza Sales 2008 – 2015
    Avastin Sales and Indication Portfolio
    Zaltrap Sales and Indication Portfolio
    Cyramza Sales and Indication Portfolio
  2) Anti-VEGF Biosuperiors of Avastin and Zaltrap
    Anti-VEGF Biosuperior Pipeline in Oncology
    Bispecific Anti-VEGF Pipeline in Oncology
  3) Anti-VEGF-R Biosuperiors of Cyramza
    Anti-VEGF-R Biosuperior Pipeline in Oncology
    Bispecific Anti-VEGF-R Pipeline in Oncology
  4) Avastin & Cyramza Biosimilar Pipeline in Oncology
  5) Marketed Anti-VEGF Products in Ophthalmology
    Lucentis & Eylea Sales 2008 – 2015
    Lucentis Sales & Indication Portfolio
    Eylea Sales & Indication Portfolio
  6) Anti-VEGF Biosuperiors of Lucentis and Eylea
    Biosuperior Anti-VEGF in Ophthalmology
    Biosuperior Bispecific Anti-VEGF and Anti-VEGF Combinations in Ophthalmology
  7) Other Anti-VEGF Molecules in Ophthalmology
  8) Lucentis Biosimilars in Ophthalmology
  9) Eylea Biosimilars in Ophthalmology
  10) Off-Label Use of Anti-VEGF in Ophthalmology
D) Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
  1. 2015 Anti-Her2 Antibody Sales
  2. Originator Anti-Her2 Antibodies
    Herceptin Approved Indications & Pipeline
    Perjeta Approved Indications & Pipeline
    Kadcyla Approved Indications & Pipeline
  3. Biosuperior Anti-Her2 Antibodies
    3rd Generation Anti-Her2 Antibodies
    Bispecific Anti-Her2 Antibodies
    Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals
  4. Biosimilar Anti-Her2 Antibodies
    Herceptin Biosimilar Antibodies
      Developments in Regulated Markets
      Development in Less Regulated Markets
  5. Perjeta Biosimilar Antibodies
E) Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update
  1. 2015 Sales of Anti-CD20 Antibodies
  2. Originator Anti-CD20 Antibodies
    Rituxan / MabThera Approved Indications & Pipeline
    Gazyva Approved Indications & Pipeline
    Arzerra Approved Indications and R&D Pipeline
    Zevalin Approved Indications
  3. Biosuperior Anti-CD20 Antibodies
    3rd Generation Anti-CD20 Antibodies
    Bispecific Anti-CD20 Antibodies
    Anti-CD20 Antibody-Drug Conjugates, Immunotoxins & Immunocytokines
  4. Biosimilar Anti-CD20 Antibodies
    Rituxan/MabThera Biosimilar Antibodies:
      Developments in Regulated Markets
      Developments in Less Regulated Markets
  5. Arzerra Biosimilar Antibodies
F) Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
  1. Sales of Anti-EGF-R Antibodies
  2. Originator Anti-EGF-R Antibodies
    Erbitux Approved Indications & Pipeline
    Vectibix Approved Indications & Pipeline
    Nimotuzumab Approved Indications & Pipeline
    Portrazza Approved Indications & Pipeline
  3. Biosuperior Anti-EGF-R Antibodies
    3rd Generation Anti-EGF-R Antibodies
    Bispecific Anti-EGF-R Antibodies
    Anti-EGF-R Antibody Drug Conjugates
  4. Biosimilar Anti-EGF-R Antibodies
    Erbitux Biosimilar Antibodies:
      Developments in Regulated Markets
      Developments in Less Regulated Markets
G) Next Wave of Biosimilar Antibodies – 2016 Update
  Abatacept Biosimilar Antibodies
  Aletuzumab Biosimilar Antibodies
  Denosumab Biosimilar Antibodies
  Eculizumab Biosimilar Antibodies
  Omalizumab Biosimilar Antibodies
  Palivizumab Biosimilar Antibodies
  Tocilizumab Biosimilar Antibodies
  Ustekinumab Biosimilar Antibodies
  Biosimilars of Immune Checkpoint Inhibitor Antibodies
H) Corporate Biosimilar & Biosuperior Therapeutic Antibody Pipelines


More Publications